key: cord-0893737-16lcm195
authors: Rahmani, Waleed; Chung, Hyunjae; Sinha, Sarthak; Bui-Marinos, Maxwell; Arora, Rohit; Jaffer, Arzina; Corcoran, Jennifer A.; Biernaskie, Jeff; Chun, Justin
title: Attenuation of SARS-CoV-2 Infection by Losartan in Human Kidney Organoids
date: 2022-01-28
journal: iScience
DOI: 10.1016/j.isci.2022.103818
sha: 9f7732bee50750e7df19f85e9826a9cf0f39f308
doc_id: 893737
cord_uid: 16lcm195

COVID-19 associated acute kidney injury (COVID-AKI) is a common complication of SARS-CoV-2 infection in hospitalized patients. The susceptibility of human kidneys to direct SARS-CoV-2 infection and pharmacologic manipulation of the renin-angiotensin II signaling (RAS) pathway modulation of this susceptibility remain poorly characterized. Using induced pluripotent stem cell derived kidney organoids, SARS-CoV-1, SARS-CoV-2 and MERS-CoV tropism, defined by the paired expression of a host receptor (ACE2, NRP1 or DPP4) and protease (TMPRSS2, TMPRSS4, FURIN, CTSB or CTSL), was identified primarily amongst proximal tubule cells. Losartan, an angiotensin II receptor blocker being tested in COVID-19 patients, inhibited angiotensin II mediated internalization of ACE2, upregulated interferon stimulated genes (IFITM1 and BST2) known to restrict viral entry, and attenuated the infection of proximal tubule cells by SARS-CoV-2. Our work highlights the susceptibility of proximal tubule cells to SARS-CoV-2 and reveals a putative protective role for RAS inhibitors during SARS-CoV-2 infection.

signed-rank test; p=0.01; Figure S3A ). The viral-host interactome genes were unperturbed by 204 RAS modulation ( Figure S3B ). 205

In murine models, RAS inhibitors upregulate surface ACE2 expression by inhibiting Ang 206 II-mediated ACE2 internalization (Deshotels et al., 2014) . To the best of our knowledge, this has 207 not been documented in human kidney tubular cells. ACE2 was primarily found on the cell 208 membrane of PTCs colocalizing with LRP2 (megalin), a tubular specific receptor expressed 209 exclusively on the apical membrane ( Figure 3A ). We observed a robust downregulation of 210 luminal ACE2 in Ang II treated organoids ( Figure 3B ). The fraction of LRP2 signal overlapping 211 with ACE2 was one-third that of vehicle control (p<0.001; Figures 3B and 3C ). There was 212 greater ACE2 signal within the cytoplasm after Ang II treatment consistent with ACE2 213 internalization ( Figure 3B ). Ang II treatment with losartan (A+L) showed a trend towards a 214 higher colocalization ACE2 with LRP2 compared to Ang II alone but did not reach statistical 215 significance. Losartan alone had no statistically significant impact on ACE2 and LRP2 216 colocalization (ANOVA Tukey post hoc test, vehicle vs losartan, p=1.0, Figures 3B and 3C) . 217

Total ACE2 levels were unchanged in human kidney organoids and human tubular epithelial 218 cells (hTECs) in response to Ang II or losartan ( Figure 3D ). This corroborates observations made 219 in human sinonasal tracts; ciliary ACE2 levels were unchanged in patients taking ACE inhibitors 220 or ARBs (Lee et al., 2020) . Taken Interestingly, losartan upregulated two ISGs, in podocytes and PTCs, known to restrict 233 coronavirus infection: BST2 (CD317/tethrin) and IFITM1 ( Figure 4B ). BST2 inhibits the cellular 234 release of hCoV-229E and SARS-CoV-1 by tethering the budding virions to the host cell 235 membrane (Taylor et al., 2015) . IFITM1 inhibits SARS-CoV-2 cell entry and is downregulated 236 in critically ill COVID-19 patients (Buchrieser et al., 2020; Hadjadj et al., 2020) . In our kidney 237 organoids, IFITM1 and BST2 were expressed in ACE2 + PTCs and upregulated by losartan 238 ( Figures 4B and 4C ). In human kidney tissue, IFITM1 and BST2 were expressed in glomeruli 239 whilst BST2 was also expressed in tubular cells ( Figure 4D ). Taken together, the upregulation of 240 antiviral ISGs like BST2 and IFITM1 by losartan may contribute to reduced susceptibility of 241 SARS-CoV-2 infection in PTCs. 242 243 J o u r n a l P r e -p r o o f

Next, we performed live virus experiments in kidney organoids to examine the impact of 245 Ang II and losartan on PTC susceptibility to SARS-CoV-2 infection. The SARS-CoV-2 246 infectious clone that expressed the reporter gene mNeonGreen was used for these experiments to 247 help visualize infected cells (Xie et al., 2020). Organoids were pretreated with vehicle, Ang II, 248 losartan or Ang II with losartan and then exposed to 10 3 or 10 5 plaque-forming units (PFU)/ml of 249 virus after 24 hours ( Figure 5A ). Supernatant collected 1.5 days post infection (dpi) were 250 reserved to assess viral titers and organoids were fixed at 3 dpi for confocal imaging ( Figure 5A ). 251

At 3 dpi we observed robust mNeonGreen signal in LTL + PTCs (Figures 5C and Figure S4 ) 252 which was absent in uninfected organoids ( Figure 5B and Figure S4 ). As expected, a significant 253 proportion of mNeonGreen was observed within the cytoplasm of ACE2 + PTCs ( Figure 5C , 254 insets ii and iii). Remarkably, PTC susceptibility to SARS-CoV-2 infection was sensitive to RAS 255 modulation ( Figure 6A -C). By 3 dpi for kidney organoids exposed to 10 3 PFU/ml SARS-CoV-2, 256

Ang II significantly increased the number mNeonGreen + LTL + cells compared to vehicle 257 controls (6.1 for Ang II vs 3.2 for control mNeonGreen + /total LTL + cells, p = 0.006) (Figures 6A  258 and 6B). Losartan alone did not diminish the number mNeonGreen + LTL + cells from control (2.5 259 vs 3.2, p = 0.844) but in combination with Ang II treatment, it significantly blunted Ang II 260 promotion of SARS-CoV-2 infectivity (6.1 for Ang II vs 3.8 for Ang II + losartan, p = 0.045) 261 ( Figure 6B ). Kidney organoids exposed to 10 5 PFU/ml 3 dpi showed similar results to 10 3 262 PFU/ml infected kidney organoids with a trend towards higher number of infected cells with Ang 263 II ( Figure 6C and Figure S4 ). We performed tissue culture infectious dose (TCID50) assays using 264 reserved culture supernatant. Kidney organoids produced infectious SARS-CoV-2 when treated 265 with vehicle in comparison to uninfected controls confirming susceptibility of kidney cells to 266 12 infection ( Figure 6D ). The median TCID50 of supernatant collected from losartan treated 267 organoids showed fewer SARS-CoV-2 infected cells with higher concentrations of losartan in a 268 dose-dependent manner ( Figure 6D ). Taken together, our findings suggest that PTCs are 269 susceptible and permissive to SARS-CoV-2 infection and this susceptibility depends on AT1R 270 signaling. Our data indicate that treatment with losartan may provide a protective advantage in 271 COVID-AKI. 272 273

In this study, we use human kidney organoids to understand the kidney tropism and 275 susceptibility to SARS-CoV-2 in response to modulation of the RAS pathway. We use scRNA-276 sequencing to perform a comprehensive expression analysis of coronavirus receptors and 277 protease which revealed that PTCs have high co-expression of several potential host receptor and 278 protease pairs. Using immunofluorescence staining of kidney organoids, we provide evidence for 279 altered ACE2 expression and localization in response treatment with Ang II and losartan. We podocytes. Related to Figure 2 and Figure S2 . 497 498 supplemented with 5% PFHM-II (Thermo Fisher, Cat. #12040077) (APEL2 + PFHM) in 558 replacement of APEL. Induced PSCs were grown on a feeder-free system using Matrigel matrix 559 coated plates. Cells were treated with 8 µM CHIR99021 (R&D Systems, Cat. #4423) for 4 days 560 followed by recombinant human FGF-9 (200 ng/mL) and heparin (1 μg/mL) for an additional 3 561 days. At day 7, cells were dissociated into single cell suspension using trypsin-EDTA (0.05%) 562

for 2 min and 250,000 or 500,000 cells were centrifuged to make a pellet at 400 x g for 2 min. 563

The pellet was transferred onto a six-well transwell plate (Corning, Cat. # 07-200-170) with four 564 or nine pellets per well, respectively. Pellets were incubated with a pulse of 5 µM CHIR99021 in 565 APEL2 + PFHM medium for 1 hr at 37 °C. After 1 hr, the medium was changed to APEL2 + 566 PFHM supplemented with FGF-9 (200 ng/mL, R&D Systems, Cat. #273-F9-025) and heparin (1 567 μg/mL, Millipore Sigma, Cat. #4784) for an additional 5 days, and then were maintained in 568 APEL2 + PFHM medium for 14 days with medium change every other day. 569 570

Treatment with RAAS modulators 571

Kidney organoids on day 28 or hTEC at passage 5 were pretreated with or without losartan (100 572 µM, Tocris, Cat. #3798) for 30 min prior to Ang II (1 µM, Millipore Sigma, Cat. #A9525) 573 treatment for 24 hr. DMSO was used as a vehicle control. Office at the University of Calgary. The icSARS-CoV-2-mNG was propagated in Vero E6 cells 582 by infecting cells in a T-175 cm 2 flask at a multiplicity of infection of 0.01 for 1 h in 2.5 mL of 583 serum-free DMEM at 37°C. Following the incubation, 17.5 mL of DMEM supplemented with 2% 584 heat-inactivated FBS and 1% PSQ (herein referred to as low-serum DMEM) was added directly 585

to the viral inoculum. The supernatant was harvested 40 -48 hpi and centrifuged at 500 × g for 10 586 min to remove cellular debris and particulates. Virus stocks were aliquoted and stored at -80°C. 587

Stock titers were determined via plaque assay using equal parts 2.4% w/v semi-solid colloidal 588 cellulose overlay (Sigma; prepared in ddH20) and 2 × DMEM (Wisent), all supplemented with 1% 589

heat-inactivated FBS and 1% PSQ (Mendoza et al., 2020). 590 591 SARS-CoV-2 infection of kidney organoids 592

On day 28, kidney organoids from 250,000 or 500,000 cells were pre-treated in duplicate with 593 vehicle, Ang II (1 μM) in presence or absence of losartan (100 μM) for 24 hr. After 24 hr, 594 organoids were infected with 10 3 or 10 5 PFU of icSARS-CoV-2-mNeonGreen (mNG) in 0.5 mL 595 or 0.25 mL of advanced RPMI medium (Thermo fisher, Cat. #12633012) for 1h. After 1h 596

incubation, organoids were washed in 0.5 mL of PBS for three times and then replenished with 597 0.5 mL of fresh RPMI medium containing Ang II (1 μM) and/or losartan (100 μM) as per 598 previous treatment. At 1.5 dpi, supernatants were collected and new fresh medium with Ang II 599 and/or losartan were added. The collected supernatant was centrifuged at 500 × g for 10 min to 600 remove cellular debris and particulates. Resulting supernatant was transferred to a new 601

Eppendorf tube and stored at -80°C for downstream viral titer analysis. At 3 dpi, organoids were 602

washed once with 0.5 mL of PBS and then fixed in 1 mL of 4% PFA for 1 h at room 603 temperature. Organoids were washed 3 times with 1 mL of PBS prior to further analysis. 604 605

Tissue Culture Infectious Dose Assay 606

Vero E6 cells were seeded in a 96-well plate at a seeding cell density of 30,000 cells/well in 607 complete DMEM. The next day, a 1:10 dilution series using 1.5 dpi supernatants was prepared in 608 low-serum DMEM, up to 7 times (10 -7 ). Medium from the 96-well plate was removed and Vero 609 E6 monolayers were exposed to 200 μL of diluted supernatant in duplicate for 5 d at 37°C with 610 5% CO2. At 5 dpi, Vero E6 cells were monitored and scored for cytopathic effects. Viral titer was 611 calculated from the plate scoring using the Kärber method (Kärber, 1931) To measure ACE2 receptor localization change upon Ang II and losartan treatment, Mander's 788 coefficient was used on ImageJ with JACoP (just another colocalization plugin). LRP2 was used 789 as a marker for proximal tubular cells that do not change localization in kidney organoids. First, 790 153 x 153 µm 2 area was selected where LRP2 is expressed in the kidney organoids. Auto-791

thresholding was applied to each channel for ACE2 and LRP2 using RenyiEntropy. 50 x 50 µm 2 792 area with relatively highest ACE2 and LRP2 signal intensities was cropped, and JACoP plugin 793 was run to measure Pearson's M1 and M2 coefficients. M2, a fraction of LRP2 overlapping with 794 ACE2 was used to indicator of localization change for ACE2 from the plasma membrane to 795 intracellular region. Two regions of interest were selected per image. In total, 7 to 13 field of 796 view were used per each treatment. 797 798

Quantification of SARS-CoV-2 infected cells in proximal tubules 799

To examine the impact of losartan on susceptibility of proximal tubular cells to SARS-CoV-2 800 infection, quantifying of SARS-CoV-2 infected cells were confined to proximal tubules. In each 801 field of view, total number of proximal tubular cells (LTL + ) and SARS-CoV-2 infected cells 802 with a robust cytoplasmic mNeonGreen (mNG) signal expression (LTL + /mNG + ) within proximal 803 tubular cells were quantified. SARS-CoV-2 positive proximal tubular cells (LTL + /mNG + ) per 804 total proximal tubular cells (LTL + ) in each field of view was expressed as a percentage. 10 field 805 of view were acquired for each treatment condition. 806 807

Statistical Analysis 808

All statistical analyses and graphical representations were performed using Microsoft Excel v16, 809 R version 3.6.3 and GraphPad Prism v8.3.0. Significance between two parametric groups was 810 determined using student's t-test. Significance between two non-parametric groups was 811 determined using Wilcoxon signed-rank test. For comparisons between multiple groups, one-way 812 ANOVA comparisons and Tukey corrections were employed. For all tests, significance was 813 defined as p value < 0.05. Single (n=1) technical replicates of each treatment were kidney 814 organoid group derived from the 1481 iPSC line were prepared for sequencing. 815 816 817

732 Nsp1: PRIM1, PRIM2, POLA1, POLA2, COLGALT1, PKP2. 733 Nsp2: EIF4E2, GIGYF2, POR, WASHC4, FKBP15, RAP1GDS1, SLC27A2 734 Nsp4: TIMM3, TIMM10, TIMM10B, TIMM29, TIMM9, IDE, ALG11, NUP210, DNAJC11 735 Nsp5: HDAC3 736 nsp5-C857A: TRMT1, GPX1 737 Nsp6: SIGMAR1, ATP6AP1, ATP5M6, ATP13A3 738 Nsp7: RAB18

765 ATP1B1 766 Orf3a: HMOX1, TRIM59, ALG5, ARL6IP6, CLCC1, SUN2, VP239, VPS11 767 Orf3b: STOML2 768 Orf6: MTCH1, NUP98, RAE1 769 Orf7a: MDN1, HEATR3 770 Orf8: EDEM3

Activator Protein-1 (AP-1)

Histopathology of Middle 820 East respiratory syndrome coronovirus (MERS-CoV) infection -clinicopathological and 821 ultrastructural study

Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical 824 Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis

Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct 828

Imbalanced Host Response to SARS-CoV-2

Drives Development of COVID-19

SARS-CoV-2 renal tropism 835 associates with acute kidney injury

Effects of losartan on renal and 838 cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England 839 journal of medicine

IFITM proteins inhibit placental 842 syncytiotrophoblast formation and promote fetal demise

Syncytia formation by SARS-CoV-2-846 infected cells

Syncytia formation by SARS-CoV-2-849 infected cells

Neuropilin-1 facilitates SARS-CoV-852 2 cell entry and infectivity

The intrarenal renin-angiotensin system in hypertension

AKI in Hospitalized Patients with COVID-19

Comparative tropism, replication kinetics, and cell damage profiling of 860 SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and 861 of COVID-19: an observational study

COVID-19: organoids go viral

Continuation 867 versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital 868 with COVID-19: a prospective, randomised, open-label trial. The Lancet

Single-cell analysis 871 reveals congruence between kidney organoids and human fetal kidney

Neuropilin-1 is a host 875 factor for SARS-CoV-2 infection

Acute Kidney Injury in Patients 878 Hospitalized With COVID-19 in

Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation 882 through an angiotensin II type I receptor-dependent mechanism

A novel angiotensin-converting enzyme-886 related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

The spectrum of kidney biopsies in 890 hospitalized patients with COVID-19, acute kidney injury, and/or proteinuria. Nephrology, 891 dialysis, transplantation : official publication of the European Dialysis and Transplant 892 Association -European Renal Association

Effect of angiotensin-converting enzyme inhibition and 895 angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology 899 and Pathophysiology

Urinary angiotensin-converting enzyme 2 in 902 hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker

The spike protein of the emerging 906 betacoronavirus EMC uses a novel coronavirus receptor for entry

TMPRSS2, and is targeted by neutralizing antibodies

Evidence that TMPRSS2 activates the severe 911 acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral 912 control by the humoral immune response

A SARS-CoV-2 protein interaction map 916 reveals targets for drug repurposing

Progression of renal disease: renoprotective specificity of 918 renin-angiotensin system blockade

Decreased Mortality of COVID-19 With Renin-921

System Inhibitors Therapy in Patients With Hypertension: A Meta-922

Impaired type I interferon activity and 925 inflammatory responses in severe COVID-19 patients

Histopathological findings and viral tropism 929 in UK patients with severe fatal COVID-19: a post-mortem study

Risk of severe COVID-19 disease with 932 ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. 933 Heart

Acute kidney injury in patients hospitalized 936 with COVID-19

A Multibasic Cleavage Site in the 938

Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

SARS-CoV-2 Cell Entry 942 Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Coronavirus Spike Protein and Tropism 945 Changes

KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and 948 Kidney

Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by 951 blockade of angiotensin II receptors

SARS-CoV-2 Orf9b suppresses type I interferon responses by 955 targeting TOM70

Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche

Perinatally administered losartan augments renal ACE2 961 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats

The intrarenal renin-964 angiotensin system: from physiology to the pathobiology of hypertension and kidney disease

Structural analysis of

CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin

Kidney Biopsy Findings in Patients with COVID-19. 971

Shared and Distinct Functions of 974

ACE2 localizes to the respiratory cilia and is not 977 increased by ACE inhibitors or ARBs

Pathophysiology of COVID-19-associated acute kidney injury

The effect of angiotensin-983 converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. The 984

Renoprotective effect of the angiotensin-receptor antagonist 987 irbesartan in patients with nephropathy due to type 2 diabetes. The New England journal of 988 medicine

Angiotensin-converting enzyme 2 is 991 a functional receptor for the SARS coronavirus

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and

Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted 996 With COVID-19: A Randomized Clinical Trial

Caution in Identifying Coronaviruses by Electron 998

Host cell entry of Middle East respiratory syndrome 1001 coronavirus after two-step, furin-mediated activation of the spike protein

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT 1006 nuclear import and antagonize interferon signaling

Inhibition of SARS-CoV-2 1010 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

IFITM proteins promote SARS-CoV-2 infection 1014 and are targets for virus inhibition in vitro

Multiorgan and Renal Tropism of 1018 SARS-CoV-2

A multi-center phase II 1021 randomized clinical trial of losartan on symptomatic outpatients with COVID-19

Single cell RNA sequencing of 13 human 1024 tissues identify cell types and receptors of human coronaviruses

Dipeptidyl peptidase 4 is a functional receptor for 1028 the emerging human coronavirus-EMC

The ORF3a protein of SARS-CoV-2 induces apoptosis in cells

Kidney Biopsy Findings in a Critically Ill

Patient With Dialysis-Dependent Acute Kidney Injury: A Case Against

Study protocol for a multicentre, prospective cohort study 1038 of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus 1039 infection

Postmortem Kidney Pathology 1042

Findings in Patients with COVID-19

Postmortem Examination of Patients With COVID-19

A diverse range of gene products are effectors of the type I interferon antiviral 1049 response

SARS-CoV-2 Nsp1 binds the ribosomal 1052 mRNA channel to inhibit translation

Cell entry 1055 mechanisms of SARS-CoV-2

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

A Single-Cell RNA Expression Map of Human 1062

Localization of 1064 ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using 1065 telmisartan

Comprehensive Integration of Single-Cell Data

Renal histopathological analysis of 26 postmortem findings of patients 1072 with COVID-19 in China

SARS-CoV-2 entry factors are highly 1075 expressed in nasal epithelial cells together with innate immune genes

Generation of kidney organoids from 1078 human pluripotent stem cells

Kidney 1081 organoids from human iPS cells contain multiple lineages and model human nephrogenesis

Severe Acute Respiratory Syndrome Coronavirus 1085

ORF7a Inhibits Bone Marrow Stromal Antigen 2 Virion Tethering through a Novel Mechanism 1086 of Glycosylation Interference

Vivo Developmental Trajectories of 1089

Human Podocyte Inform In Vitro Differentiation of Pluripotent Stem Cell-Derived Podocytes

Hypertension delays viral clearance and 1093 exacerbates airway hyperinflammation in patients with COVID-19

Proteomics. Tissue-based map 1097 of the human proteome

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. The 1100

Endothelial cell infection and 1103 endotheliitis in COVID-19

SARS-CoV-2 causes a specific dysfunction of the kidney 1106 proximal tubule

Virological assessment of hospitalized 1109 patients with COVID-2019

A Novel Soluble ACE2 Variant with Prolonged Duration of Action 1112 Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids

Long Term Culture of 1115

Human Kidney Proximal Tubule Epithelial Cells Maintains Lineage Functions and Serves as an 1116

Ex vivo Model for Coronavirus Associated Kidney Injury

TMPRSS2 1120 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and 1124

Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension 1125 Hospitalized With COVID-19

J o u r n a l P r e -p r o o f